Concor AM (5/5 mg) Tablet is a combination medicine used for the Currently I am taking concor Cor mg since 2 months for palpitations. ulotka firmy Merck (),. * Pharmindex Brevier /1. Prices of different Concor (5mg, 30 tabl.) – 24,19 PLN. • Concor Cor (5mg, 30 tabl.) – 23,79 PLN. Patient information for CARDICOR MG TABLETS Including dosage instructions and possible side effects.
|Published (Last):||22 March 2007|
|PDF File Size:||19.54 Mb|
|ePub File Size:||19.48 Mb|
|Price:||Free* [*Free Regsitration Required]|
Qualitative and quantitative composition Cardicor 1. Each tablet contains 1. Each tablet contains 2. U,otka tablet contains 3. Each tablet contains 5 mg bisoprolol fumarate Cardicor 7.
CARDICOR 2.5MG TABLETS
Each tablet contains 7. Each tablet contains 10 mg bisoprolol fumarate For ulitka full list of excipients, see section 6. Pharmaceutical form Film-coated tablet. Patients should be stable without acute failure when bisoprolol treatment is initiated. It is recommended that the treating physician should be experienced in the management of chronic heart failure.
Transient worsening of heart failure, hypotension, or bradycardia may occur during the titration period and thereafter. The treatment of stable chronic heart failure with bisoprolol requires a titration phase The treatment with bisoprolol is to be started with a gradual uptitration according to the following steps: The maximum recommended dose is 10 mg once daily.
Close monitoring of vital signs heart rate, blood pressure and symptoms of worsening heart failure is recommended during the titration phase. Symptoms may already occur within the first day after initiating the therapy. If the maximum recommended dose is not well tolerated, gradual dose reduction may be considered.
In case of transient worsening of heart failure, concr, or bradycardia reconsideration of the dosage of the concomitant medication is recommended. It may also be necessary to temporarily lower the dose of bisoprolol or to consider discontinuation. If discontinuation is considered, gradual dose decrease is recommended, since abrupt withdrawal may lead to acute deterioration of the patients condition.
Treatment of stable chronic heart failure with bisoprolol is generally a long-term treatment. Patients with hepatic or renal impairment. There is no information regarding pharmacokinetics of bisoprolol in patients with chronic heart failure and with impaired hepatic or renal function.
Uptitration of the dose in these populations should therefore be made with additional caution. There is no paediatric experience cncor bisoprolol, therefore its use cannot be recommended in paediatric patients. Bisoprolol tablets should be taken in the morning and can be taken with food. They should be swallowed with liquid and should not be chewed.
Especially in patients with ischaemic heart disease the cessation of therapy with bisoprolol must not be done abruptly unless clearly indicated, because this may lead to transitional worsening of heart condition.
The initiation and cessation of treatment with bisoprolol necessitates regular monitoring. There is no therapeutic experience of bisoprolol treatment of heart failure in patients with the following diseases and conditions: As with other beta-blockers, bisoprolol may increase both the sensitivity towards allergens and the cnocor of anaphylactic reactions.
Epinephrine treatment does not always yield the expected therapeutic effect. Aggravation of symptoms may occur especially when starting therapy. It is currently recommended that maintenance beta-blockade cincor continued peri-operatively.
Serevent® Dysk – ulotka (dawkowanie, zastosowanie, interakcje) –
The anaesthesist must be aware of beta-blockade because of the potential for interactions with other drugs, resulting in bradyarrhythmias, attenuation of the reflex tachycardia and the decreased reflex ability to compensate for blood loss. If it is thought necessary to withdraw beta-blocker therapy before surgery, this should be done gradually and completed about 48 hours before anaesthesia.
Combination of bisoprolol with calcium antagonists of the verapamil or diltiazem type, with Class I antiarrhytmic drugs and with centrally acting antihypertensive drugs is generally not recommended, for details please refer to section 4.
Although cardioselective beta1 beta-blockers may have less effect on lung function than non-selective beta-blockers, as with all beta-blockers, these should be avoided in patients with obstructive airways diseases, unless there are compelling clinical reasons for their use. Where such reasons exist, Cardicor may be used with caution.
Cardicor 1.25mg Film Coated Tablets
In patients with obstructive airways diseases, the treatment with bisoprolol should be started at the lowest possible dose and patients should be carefully monitored for new symptoms e.
In bronchial asthma or other chronic obstructive lung diseases, which may cause symptoms, bronchodilating therapy should be given concomitantly.
Occasionally an increase of the airway resistance may occur in patients with asthma, therefore the dose of beta 2 -stimulants may have to be increased. Patients with psoriasis or with a history of psoriasis should only be given beta-blockers e.
In patients with phaeochromocytoma bisoprolol must not be administered until after alpha-receptor blockade. Under treatment with bisoprolol the symptoms of a thyreotoxicosis may be masked. Calcium antagonists of the verapamil type and to a lesser extent of the diltiazem type: Negative influence on contractility and atrio-ventricular conduction. Class I antiarrhythmic drugs e. Effect on atrio-ventricular conduction time may be potentiated and negative inotropic effect increased. Centrally acting antihypertensive drugs such as clonidine and others e.
Concomitant use of centrally acting antihypertensive drugs may worsen heart failure by a decrease in the central sympathetic tonus reduction of heart rate and cardiac output, vasodilation.
Combinations to be used with caution. Calcium antagonists of the dihydropyridine ocncor such as felodipine and amlodipine: Concomitant use may increase the risk ccor hypotension, and an increase in the risk of a further deterioration of the ventricular pump function in patients with heart failure cannot be excluded.
Class-III antiarrhythmic drugs e. Effect on atrio-ventricular conduction time may be potentiated. Concomitant use may increase atrio-ventricular conduction time and the risk of bradycardia. Insulin and oral antidiabetic drugs: Increase of blood sugar lowering effect. Blockade of beta-adrenoreceptors may mask symptoms of hypoglycaemia. Attenuation of the reflex tachycardia and increase of the risk of hypotension for further information on general anaesthesia see also section 4.
Reduction of heart rate, increase of atrio-ventricular conduction time. NSAIDs may reduce the hypotensive effect of bisoprolol. Combination with bisoprolol may reduce the effect of both agents.
Ullotka use with ulotkz agents as well as with other drugs with blood pressure lowering potential e. Combinations to be considered. Enhanced hypotensive effect of the beta-blockers but also risk for hypertensive crisis.
In general, beta-adrenoceptor blockers reduce placental perfusion, which has been associated with growth retardation, intrauterine death, abortion or early labour.
If treatment with beta-adrenoceptor blockers is necessary, beta 1 -selective adrenoceptor blockers are preferable. Bisoprolol should not be used during pregnancy unless clearly necessary.
If treatment with bisoprolol is considered necessary, the uteroplacental blood flow and the fetal growth should be monitored. In case of conncor effects on pregnancy or the fetus alternative treatment should be considered. The newborn infant must be closely monitored. Symptoms of hypoglycaemia and bradycardia are generally to be expected within the first 3 days.
It is not known whether this drug is excreted in human milk. Therefore, breastfeeding is not recommended during administration of bisoprolol. However, due to individual variations in reactions to the drug, the ability to drive a vehicle or to operate machinery may be impaired. This should be considered particularly at start of treatment and upon change of medication as well as in conjunction with alcohol.
Ear and labyrinth disorders: Respiratory, thoracic and mediastinal disorders: Skin and subcutaneous tissue disorders: Beta-blockers may provoke or worsen psoriasis or induce psoriasis-like rash Musculoskeletal and connective tissue disorders: Reproductive system and breast disorders: Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
Healthcare professionals are asked ulotkw report any suspected adverse reactions via the Yellow Card Scheme at www.
Concor Cor |
In general the most common signs expected with overdosage of a beta-blocker are bradycardia, hypotension, bronchospasm, acute cardiac insufficiency and hypoglycaemia.
To date a few cases of overdose maximum: There is a wide interindividual variation in sensitivity to one single high dose of bisoprolol and patients with heart failure are probably very sensitive. Therefore it is mandatory to initiate the treatment of these patients with a gradual uptitration according to the scheme given in section 4. If overdose occurs, bisoprolol treatment should be stopped and supportive and symptomatic treatment should be provided.
Limited data suggest that bisoprolol is hardly dialysable. Based on the expected pharmacologic actions and recommendations for other beta-blockers, the following general measures should be considered when clinically warranted. If the response is inadequate, isoprenaline or another agent with positive chronotropic properties may be given cautiously. Under some circumstances, transvenous pacemaker insertion may be necessary. Intravenous fluids and vasopressors should be administered.
Intravenous glucagon may be useful. AV block second or third degree: Patients should be carefully monitored and treated with isoprenaline infusion or transvenous cardiac pacemaker insertion.
Acute worsening of heart failure: Beta blocking agents, selective ATC Code: